Doses of PCV7 | Doses of PHiD-CV10 | |
|---|
0 | 1 | 2 | 3 | 4 | TOTAL |
|---|
0 | 33e
| 18 e
| 50 | 284 | 77 | 411 |
1 | 5 e
| 2 e
| 23 | 16 | 1 | 40 |
2 | 28 | 15 | 30 e
| | | 43 |
3 | 322 | 73 | 1 e
| | | 395¥
|
4 | 5 | 1 | | | | 6 |
+ PPV23§
| 138§
| | | | | |
+ PCV13¥
| 2¥
| 0 | 19¥
| 70¥
| 1¥
| 92¥
|
TOTAL
| 355 | 89 | 73 | 300 | 78 | 895 |
- PCV7, 7-valent pneumococcal conjugate vaccine.
- PHiD-CV10, 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine.
- PCV13, 13-valent pneumococcal conjugate vaccine.
- Included mixed schedules:
-
§138 children also received one dose PPV23: (ceased in October 2010) 138 of 177 PCV7 3-dose children who were age-eligible for PPV23.
-
¥92 children also received one dose PCV13:
- 2 of 322 PCV7 3-dose children.
- 19 of 50 PHiD-CV10 2-dose children.
- 70 of 284 PHiD-CV10 3-dose children.
- 1 of 77 PHiD-CV10 4-dose child.
- Excluded schedules
-
e91 children were excluded, including two additional children (not shown in Table 2) who received two doses of PHiD-CV10 and two doses of PCV13.
